A case of acute pulmonary thromboembolism after taking tadalafil.

Tuberc Respir Dis (Seoul)

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Lung Institute, Seoul National University College of Medicine, Seoul, Korea.

Published: October 2012


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Tadalafil is a phosphodiesterase-5 inhibitor (PDE5I), which is widely used to treat erectile dysfunction. Although PDE5Is have excellent safety profiles, and most of the side effects are mild, rare serious adverse events have been reported in association with PDE5Is. Thrombosis is one of those events, and a few previous reports have suggested the association of PDE5Is with thrombosis. We report the case of a 61-year-old male who developed pulmonary embolism combined with pulmonary infarction directly after taking tadalafil. Both the patient and the physician suspected tadalafil as the culprit drug, as the patient was in an otherwise healthy condition. However, after extensive evaluation, we noticed that factor VIII levels were elevated. Prior reports suggesting the association between thrombosis and PDEIs either lack complete information on coagulation factors, or show inconsistencies in their results. Physicians should operate caution prior to accepting the diagnosis of adverse drug reaction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492424PMC
http://dx.doi.org/10.4046/trd.2012.73.4.231DOI Listing

Publication Analysis

Top Keywords

association pde5is
8
pde5is thrombosis
8
case acute
4
acute pulmonary
4
pulmonary thromboembolism
4
tadalafil
4
thromboembolism tadalafil
4
tadalafil tadalafil
4
tadalafil phosphodiesterase-5
4
phosphodiesterase-5 inhibitor
4

Similar Publications

Oral drug treatments of erectile dysfunction: a AFU/SFMS systematic review.

Fr J Urol

September 2025

Department of urology, Maison de Santé Protestante de Bordeaux-Bagatelle, Talence, France; Department of urology, HIA Robert-Picqué, Villenave d'Ornon, France.

Objectives: To evaluate the efficacy and safety of oral phosphodiesterase-5 inhibitors (PDE5Is) in the treatment of erectile dysfunction (ED). Additionally, to compare various PDE5Is and assess their suitability for different patient populations.

Evidence Acquisition: A systematic review of literature published from January 1999 to January 2023 was conducted following the PICOS criteria.

View Article and Find Full Text PDF

Background And Objective: The Current European Association of Urology guidelines do not provide recommendation for combination of regenerative therapies with standard therapies for erectile dysfunction. The aim of this study was to compare the efficacy of combined regenerative therapy with monotherapy for erectile dysfunction.

Methods: A systematic review and meta-analysis were conducted following the 2020 Preferred Reporting Items for Systematic Reviews and Meta Analyses guidelines.

View Article and Find Full Text PDF

Background: Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. The PVRI GoDeep meta-registry collects real-world data of PH patients from international PH referral centers.

Methods: ILD-PH patients and relevant subgroups (IIP, IPF) were stratified by pulmonary vascular resistance (PVR).

View Article and Find Full Text PDF

Background: Erectile dysfunction (ED) affects the physical and psychological health of a patient and his partner and can have a significant negative impact on their quality of life. Second-line therapies for ED include intracavernosal injections of vasoactive drug (ICIVAD) among others.

Aims: The aim of this study was to assess the efficacy of combination of papaverine and chlorpromazine (bimix) for the treatment of ED in patients who are unresponsive to 5-Phosphodiestrase inhibitors (PDE5-I).

View Article and Find Full Text PDF

Bariatric surgery involves major changes in the anatomy and physiology of the gastrointestinal tract, which may alter oral drug bioavailability and efficacy. Phosphodiesterase-5 inhibitor (PDE5i) drugs are the first-line treatment of erectile dysfunction, a condition associated with a higher BMI. In this paper, we examine the PDE5i vardenafil for possible post-bariatric changes in solubility/dissolution and absorption.

View Article and Find Full Text PDF